CytoMed Therapeutics (CytoMed Therapeutics) Common Stock : $17.81 Mil (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics Common Stock?

CytoMed Therapeutics's quarterly common stock increased from Dec. 2022 ($6.59 Mil) to Jun. 2023 ($17.62 Mil) and increased from Jun. 2023 ($17.62 Mil) to Dec. 2023 ($17.81 Mil).

CytoMed Therapeutics's annual common stock increased from Dec. 2021 ($4.80 Mil) to Dec. 2022 ($6.59 Mil) and increased from Dec. 2022 ($6.59 Mil) to Dec. 2023 ($17.81 Mil).

CytoMed Therapeutics Common Stock Historical Data

The historical data trend for CytoMed Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoMed Therapeutics Common Stock Chart

CytoMed Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Common Stock

2.63

4.80

6.59

17.81

CytoMed Therapeutics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Common Stock	Get a 7-Day Free Trial			4.80	5.56	6.59	17.62	17.81

CytoMed Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

CytoMed Therapeutics (CytoMed Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (NAS:GDTC) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

F98:Germany

Address

1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544

Website

https://w2.cytomed.sg

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.

Executives

Chee Kong Choo	director, 10 percent owner	COMMONWEALTH LANE 08-22, SINGAPORE U0 149544
Jieming Zeng	director, officer: CSO and CMO	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Shu Wang	10 percent owner	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Wee Kiat Tan	director, officer: Chief Operating Officer	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Keng Kiat Toh	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Glorious Finance Ltd	10 percent owner	18 NAMLY GROVE SOUTH, SINGAPORE U0 267310
Luk Lucas Tien Wee	director, officer: Chief Clinical Officer	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Leong Mark Kei Wei	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Chak Hua Yew	director	1 COMMONWEALTH LANE #08-22, SINGAPORE U0 149544
Yuin Han Loh	director	1 COMMONWEALTH LANE 08-22, SINGAPORE U0 149544